Press release dated November 17, 2026, titled "Sai Parenterals Wholly Owned Subsidiary SP Analytics enters an…
As filed · Sai Parenterals Limited has informed the Exchange regarding a press release dated November 17, 2026, titled "Sai Parenterals Wholly Owned Subsidiary SP Analytics enters an agreement to Acquire Majorit
What happened
FactA press release dated November 17, 2026, titled "Sai Parenterals Wholly Owned Subsidiary SP Analytics enters an agreement to Acquire Majority Stake in Bion Therapeutics Prescription Business . ". Unit: Sai Parenteral’s Limited. SP Analytics enters an agreement to Acquire Majority Stake in Bion Therapeutics.
Why it matters
CapitSignal interpretationAn acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
RevisedQ4FY26 revenue stood at X197.93 crores with growth of 166.65% on Q-o-Q basis; EBITDA stood at X28.97 crores with growth of 366.97% on Q-o-Q basis; PAT stood at X13.25 crores with growth of 736.04% on Q-o-Q basis;
FY26 revenue stood at X380.99 crores with growth of 140.37% on Y-o-Y basis; EBITDA stood at X47.21 crores with growth of 33.29% on Y-o-Y basis; and PAT stood at X14.37 crores with growth of 45.52% on Y-o-Y basis
Change
FactImplication
CapitSignal interpretationMargins
RevisedStandalone revenue stood at X164.99 crores for FY26 with growth of 30.65% on Y-o-Y basis; EBITDA stood at X33.32 crores with growth of 22.63% on Y-o-Y basis; PAT stood at X16.86 crores with growth of 63.61% on Y-o-Y basis;
More importantly, our profitability has improved dramatically, EBITDA grew 366.79% in Q4 and PAT surged 736% — clear evidence of the operating leverage in our model.
Change
FactImplication
CapitSignal interpretationMargins
RevisedMore importantly, our profitability has improved dramatically, EBITDA grew 366.79% in Q4 and PAT surged 736% — clear evidence of the operating leverage in our model.
For the full year, EBITDA grew 33.29% and PAT grew 45.52%.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Consideration and how it is funded
- Revenue and profit of the target
- Expected completion date
- With ongoing capex of ~%440 crores expected to be completed in FY27, we believe the company is well positioned (management committed by FY27)
- The Construction of Australia’s largest and most modern pharmaceutical plant built with Capex of AUD 53 millio (management committed by Q4FY27)
Evidence
- Sai Parenterals Limited has informed the Exchange regarding a press release dated November 17, 2026, titled "Sai Parenterals Wholly Owned Subsidiary SP Analytics enters an agreement to Acquire Majority Stake in Bion Therapeutics Prescription Business . ".(opens the original filing in a new tab)
- Earlier statement · Q4 FY26
- Latest statement · Q4 FY26
- Earlier statement · Q4 FY26
- Latest statement · Q4 FY26
- Earlier statement · Q4 FY26
- Latest statement · Q4 FY26
How CapitSignal classified this
- Reasoning:
- ACQUISITION base 74; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%